Charles River re-ups Chiesi drug discovery contract

By Melissa Fassbender contact

- Last updated on GMT

Charles River re-ups Chiesi drug discovery contract

Related tags: Pharmacology

Charles River Laboratories has extended its integrated respiratory program with Chiesi Farmaceutici, through which it identifies and tests candidates for preclinical development.

Parma, Italy-based Chiesi Farmaceutici SpA researches, develops, and markets drugs in the respiratory therapeutics, specialist medicine, and rare diseases areas.

According to the early-stage contract research organization (CRO), the integrated respiratory program with Chiesi was established in 2011.

In the first six years, our relationship has yielded a number of patents and development candidates, and we’re optimistic that this strategic continuation will allow us to continue working on promising candidates with Chiesi​,” Birgit Girshick, Corporate Senior Vice President, Global Discovery at Charles River, told

With the continuation, we’ll provide them an extensive portfolio of integrated drug discovery capabilities​,” added Girshick.

Provided services include medicinal chemistry, ADME/DMPK studies, pharmaceutics, in vitro assays, in vivo models, and safety pharmacology studies.

(Feature image: iStock/Pinkypills)

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us


View more